PE-22-28 vs GHRP-2
Side-by-side comparison of key properties, dosing, and research.
- Summary
- PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
- GHRP-2 is a potent synthetic hexapeptide that stimulates growth hormone release by activating ghrelin receptors in the pituitary and hypothalamus. It produces one of the strongest GH pulses among GHRPs, though unlike Ipamorelin it does cause modest increases in cortisol and prolactin.
- Half-Life
- Relatively short; CNS effects may persist due to neurogenic mechanisms
- 15–60 minutes
- Admin Route
- SubQ, Intranasal
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 200–400 mcg
- 100–300 mcg
- Frequency
- Once daily
- 2–3 times daily
- Key Benefits
- Rapid-onset antidepressant effects (within 24 hours)
- Promotes hippocampal neurogenesis
- Improves cognitive performance and memory
- Reduces anxiety and depressive behavior
- Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
- May help treatment-resistant depression
- Neuroprotective effects
- Strong GH pulse stimulation
- Increased IGF-1 levels
- Enhanced muscle growth and recovery
- Improved fat metabolism
- Better sleep quality
- Increased bone density
- Enhanced appetite (less pronounced than GHRP-6)
- Anti-aging effects via GH axis optimization
- Side Effects
- Generally well tolerated in animal models
- Limited human data available
- Possible mild headache or transient mood changes at initiation
- Injection site reactions (SC)
- Increased appetite
- Water retention
- Elevated cortisol (modest)
- Elevated prolactin (modest)
- +2 more
- Stacks With
- —
- —